At the time of writing, Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $15.91, up 1.02%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling.
From an analyst’s perspective:
Previously, Morgan Stanley upgraded its rating to Overweight on September 20, 2024, and elevated its price target to $26. On September 19, 2024, B. Riley Securities initiated with a Buy rating and assigned a price target of $33 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $14 on July 18, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $11 on November 15, 2023. Morgan Stanley upgraded its rating to Equal-Weight for this stock on October 26, 2023, and upped its price target to $8. In a note dated June 21, 2023, Evercore ISI initiated an Outperform rating.
For the past year, the stock price of Centessa Pharmaceuticals plc ADR fluctuated between $7.75 and $19.09. Currently, Wall Street analysts expect the stock to reach $23.25 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $15.91 at the most recent close of the market. An investor can expect a potential return of 46.13% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.43%, Pretax Profit Margin comes in at -22.95%, and Net Profit Margin reading is -23.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.52 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.52 points at the first support level, and at 15.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.25, and for the 2nd resistance point, it is at 16.60.
Ratios To Look Out For
It is important to note that Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] has a current ratio of 21.52. In addition, the Quick Ratio stands at 21.52 and the Cash Ratio stands at 14.96. Considering the valuation of this stock, the price to sales ratio is 303.14, the price to book ratio is 4.20.
Transactions by insiders
Recent insider trading involved Weinhoff Gregory M, Chief Business Officer, that happened on Feb 25 ’25 when 11494.0 shares were sold. Officer, Weinhoff Gregory M completed a deal on Feb 25 ’25 to buy 11494.0 shares. Meanwhile, Chief Executive Officer SAHA SAURABH sold 55000.0 shares on Feb 20 ’25.
